Señales en vivo de BIVI | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States...

Stats
Volumen de hoy	312 670
Volumen promedio	2.59M
Capitalización de mercado	26.63M
EPS	$0 ( 2024-02-09 )
Próxima fecha de ganancias	( $-0.330 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.410
ATR14	$0.00300 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Do Cuong V	Buy	10 000	Common stock
2024-03-04	Do Cuong V	Buy	5 000	Warrants (right to buy)
2023-12-11	Kim Joanne Wendy	Buy	5 000	Common Stock
2023-11-09	Lang James Paul	Buy	93 500	Stock Option (right to buy)
2023-11-09	Gorlin Steve	Buy	46 358	Common Stock

INSIDER POWER
91.52
Last 94 transactions
Buy: 39 235 676 \| Sell: 4 917 434

Volumen Correlación

Largo: -0.03 (neutral)

Corto: -0.22 (neutral)

Signal:(48.226) Neutral

Biovie Inc Correlación

10 Correlaciones Más Positivas
IONM	0.843
CIDM	0.823
AACG	0.818
GAINL	0.807
CERC	0.806
AMRB	0.802

10 Correlaciones Más Negativas
DBX	-0.895
RMRM	-0.894
PCT	-0.882
PTC	-0.866
NOVT	-0.864
OPEN	-0.861
CVAC	-0.846
XP	-0.845
FTHM	-0.842
EXPI	-0.842

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Biovie Inc Correlación - Moneda/Commodity

0.00
( neutral )

-0.01
( neutral )

Biovie Inc Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-266 842 (0.00 %)
EPS:	$-1.550

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-266 842 (0.00 %)
EPS:	$-1.550

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-237 421 (0.00 %)
EPS:	$-0.920

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-10.50

Financial Reports:

No articles found.

Biovie Inc

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.